Navigation Links
Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Date:4/24/2012

is ongoing and we expect HOT to enter Phase 2 trials in the first quarter of 2013 as a monotherapy for solid tumors with significant unmet medical need, subject to additional funding. CLR1404 (COLD), a pre-clinical cancer-targeted non-radioactive chemotherapy, works primarily through Akt inhibition. Together, we believe our compounds are able to "find, treat and follow" cancer anywhere in the body in a novel, effective and highly selective way. For additional information please visit www.novelos.com.INVESTOR CONTACTSJ. Patrick Genn, Vice President of IR

Anne Marie Fields, Senior Vice PresidentNovelos Therapeutics, Inc.

LHAPh: (858) 775-7456

Ph: (212) 838-3777Email: jpgenn@novelos.com

Email: afields@lhai.com, @LHA_IR_PRNovelos Therapeutics, Inc.

Madison, WI
Boston, MA

This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FD
'/>"/>

SOURCE Novelos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nonconformity of NOV002 Used in Phase 3 NSCLC Trial Sponsored by Novelos Therapeutics, Inc to NOV002 (Glutoxim(R)), Used in Phase 1/2 NSCLC and all Previous Trials
2. Novelos Therapeutics to Present at the 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on June 16
3. Novelos Therapeutics Announces Dismissal of Putative Federal Securities Class Action Lawsuit
4. Novelos Therapeutics Prices $5.9 Million Public Offering
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
8. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
9. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
10. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) ... focus on Omega-3 therapies for cardiovascular disease (CVD) ... financial results for the three months ended March ... in Canadian dollars unless otherwise stated. ... despite its limited financial resources," stated Mr. ...
(Date:6/1/2015)... 2015 The nuclear imaging market is estimated ... CAGR of 12.08%. Nuclear medicine is the use of ... types of Nuclear imaging used commonly are PET and ... for nuclear medicine applications like nuclear cardiology procedures. However, ... global shortage of molybdenum-99 isotope which is in turn ...
(Date:6/1/2015)... Nevro Corp. (NYSE: NVRO ), a ... solutions for the treatment of chronic pain, today announced ... its common stock consisting of 1,475,506 shares to be ... by certain of its stockholders. In addition, Nevro expects ... up to an additional 590,202 shares of common stock ...
Breaking Medicine Technology:Pivotal Therapeutics Announces First Quarter Financial Results 2Pivotal Therapeutics Announces First Quarter Financial Results 3Pivotal Therapeutics Announces First Quarter Financial Results 4Pivotal Therapeutics Announces First Quarter Financial Results 5North America Nuclear Imaging Market - Growth, Trends And Forecasts (2014 - 2019) 2North America Nuclear Imaging Market - Growth, Trends And Forecasts (2014 - 2019) 3Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3
... Mich., Jan. 20, 2011 Perrigo Company (Nasdaq: PRGO; ... agreement to acquire substantially all of the assets of ... marketer of generic pharmaceutical products for approximately $540 million ... benefit as a result of the acquisition of Paddock,s ...
... Reportlinker.com announces that a new market research report ... Hospital Radiography & Fluoroscopy Census ... the most comprehensive European market report on the ... Mammography, R&F, Angiography, CT, MRI,) and radiology IT ...
Cached Medicine Technology:Perrigo to Acquire Assets of Paddock Labs for $540 Million 2Perrigo to Acquire Assets of Paddock Labs for $540 Million 3Perrigo to Acquire Assets of Paddock Labs for $540 Million 4Perrigo to Acquire Assets of Paddock Labs for $540 Million 5Reportlinker Adds Hospital Radiography & Fluoroscopy Census 2
(Date:6/1/2015)... Texas (PRWEB) June 01, 2015 Unlike most ... as three times for in-use periods compared to when the ... monthly rate whether the client uses the generator or not. ... availability and delivery in as little as a few hours ... desire to store a portable generator onsite. , “Even minor ...
(Date:6/1/2015)... On May 14, 2015, the ... the Cherry Creek Chamber of Commerce for the grand ... centers typically do not offer primary care services by ... Creek Urgent Care staff to schedule family care procedures, ... to 7:30 p.m. the center hosted presidents, CEOs, and ...
(Date:6/1/2015)... June 01, 2015 Sharenote, a leading ... for the Healthcare Industry this week in Louisiana. The ... in four days to provide potential providers with the ... profitability, and monitor risk within their network. , ... and is being used by more than 250 practices. ...
(Date:6/1/2015)... There’s never a good time to be ... non-emergency, minor illnesses. , As of June 1, OSF HealthCare ... medical care via the Internet. Patients throughout Illinois can access ... , “Everyone is busy. We know that getting in to ... want to make it easier,” said Jeffry Tillery, MD, Chief ...
(Date:6/1/2015)... Hexagon Geospatial is pleased to announce the launch ... service that provides on-demand access to the company’s world-class ... IMAGINE and GeoMedia are now available ... subscription model for delivering software products as an online ... quickly and easily access the right tools that help ...
Breaking Medicine News(10 mins):Health News:Worldwide Power Products Offers “Budget Billing” Contingency Generator Rental Program; Guarantees Power for Peak of Hurricane Season and Beyond 2Health News:Grand Opening For AFC/Doctors Express Cherry Creek Primary Care Clinic 2Health News:OSF HealthCare Now Offering OSF OnCall 2Health News:OSF HealthCare Now Offering OSF OnCall 3Health News:Hexagon Geospatial Launches Cloud-Based Producer Online Suite 2Health News:Hexagon Geospatial Launches Cloud-Based Producer Online Suite 3
... the drug Tamiflu to avert the bird flu outbreak ... February 2006//. ,Scientists at the High Security ... and genetic analysis of virus collected from Jalgaon and ... to Tamiflu due the different types of amino acids ...
... Integrated Counselling and Testing Centres at Government General Hospitals ... with the Indian Public Health Standards (IPHS), draft guidelines ... aim to spread awareness about AIDS in the susceptible ... 2006 report on the global AIDS epidemic, 486 fresh ...
... month, The Medicines and Healthcare products Regulatory Agency ... amendment it is now possible to market homoeopathic ... and therapeutic application of remedies in question. This ... who have written off homoeopathy as ‘mumbo jumbo’ ...
... from Drexel University and the University of Brighton in ... improve the treatment of sepsis. // ... or severe trauma that results in 1,500 deaths worldwide ... lung and breast cancers. Sepsis occurs when proteins called ...
... Jude Children's Research Hospital have discovered in mouse models ... earliest critical regulators // controlling lens development in the ... have been previously identified in patients with holoprosencephaly, a ... called the cerebrum to fail to divide normally into ...
... of cognitive decline experienced by several cancer patients receiving ... on the // effect of chemotherapy on cognitive functions ... Baycrest Research Centre for Aging and the Brain carried ... Drs. Ian Tannock and Janette Vardy of Princess Margaret ...
Cached Medicine News:Health News:Bird flu outbreak prevented by Tamiflu 2Health News:Anti-HIV drive intensified in Haryana 2Health News:Hostility breeds against Homeopathy in England following new regulations 2Health News:Drexel Research in Cytokines Could Treat Sepsis 2Health News:Key Gene Controlling Eye Lens Development Identified 2Health News:Chemo drugs cause cognitive decline in breast cancer patients 2
The new ProteomeX Workstation enables the rapid set up, execution and analysis of multidimensional LC/MS methods, providing you with the best possible technique to characterize your complex proteomic...
Storage temperature: 2 - 8C, linearity: 0 - 700 mg/dL, expected values: 30 - 780 mg/dL. Available with calibrator and number of tests 110....
Alkaline phosphatase FS (DGKC new; 37C). For determination of alkaline phosphatase (ALP) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
For the direct colorimetric determination of alkaline phosphatase in human serum....
Medicine Products: